Pharmacoeconomic review report: Naltrexone hydrochloride and bupropion hydrochloride (Contrave) (Bausch Health, Canada iInc.) :indication: an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia)

Naltrexone and bupropion (NB; Contrave) is a fixed-dose combination oral tablet indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who are obese (body mass index [BMI]: ≥ 30 mg/kg2); or overweight (BMI: ≥ 27 mg/kg2) with the pres...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2020, July 2020
Edition:Version: Final
Series:CADTH common drug review
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02407nam a2200253 u 4500
001 EB002001729
003 EBX01000000000000001164630
005 00000000000000.0
007 tu|||||||||||||||||||||
008 210907 r ||| eng
245 0 0 |a Pharmacoeconomic review report: Naltrexone hydrochloride and bupropion hydrochloride (Contrave)  |h Elektronische Ressource  |b (Bausch Health, Canada iInc.) :indication: an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia) 
246 3 1 |a Naltrexone hydrochloride and bupropion hydrochloride (Contrave) 
246 3 1 |a Pharmacoeconomic review report for naltrexone hydrochloride and bupropion hydrochloride (Contrave) 
250 |a Version: Final 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2020, July 2020 
300 |a 1 PDF file (29 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK565298  |3 Volltext 
082 0 |a 610 
520 |a Naltrexone and bupropion (NB; Contrave) is a fixed-dose combination oral tablet indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who are obese (body mass index [BMI]: ≥ 30 mg/kg2); or overweight (BMI: ≥ 27 mg/kg2) with the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia). It is available in one combined strength: 8 mg naltrexone hydrochloride and 90 mg bupropion hydrochloride. The recommended dosage for NB is two tablets twice daily. At the submitted price of $2.21 per tablet, the annual cost is expected to be $3,234. The sponsor's reimbursement request was as per the indication. The sponsor submitted a cost-utility analysis comparing NB taken in conjunction with standard management (SM; defined as a reduced-calorie diet and increased physical activity) to SM alone